Search - tctmd.com

Displaying 21 - 40 of 379

Sort: Relevancy | Date

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Daily News

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Yael L. Maxwell

April 16, 2025

News Daily News

Cardiotoxicity Rare With Common GI Chemotherapy

L.A. McKeown

April 15, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Opinion CV Team Dispatch

March 2025 Dispatch for the CV Team

L.A. McKeown

March 21, 2025

News Daily News

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

Michael O'Riordan

March 18, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Use of Secondary CVD Prevention Meds Still Meager Worldwide

Caitlin E. Cox

February 03, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Aspirin Use for Primary Prevention Declining in US: NHANES

Michael O'Riordan

January 24, 2025

News Opinion CV Team Dispatch

December 2024 Dispatch for the CV Team

L.A. McKeown

December 20, 2024

News Daily News

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

Todd Neale

December 06, 2024

News Daily News

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

Todd Neale

December 04, 2024

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

News Daily News

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Michael O'Riordan

November 13, 2024

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Opinion CV Team Dispatch

October 2024 Dispatch for the CV Team

L.A. McKeown

October 25, 2024

News Daily News

Study Validates Accuracy of PREVENT for CVD Mortality Risk Prediction

Todd Neale

October 15, 2024

Advertisement

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Cardiotoxicity Rare With Common GI Chemotherapy

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

March 2025 Dispatch for the CV Team

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Use of Secondary CVD Prevention Meds Still Meager Worldwide

January 2025 Dispatch for the CV Team

Aspirin Use for Primary Prevention Declining in US: NHANES

December 2024 Dispatch for the CV Team

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

November 2024 Dispatch for the CV Team

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

October 2024 Dispatch for the CV Team

Study Validates Accuracy of PREVENT for CVD Mortality Risk Prediction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content